호산구성 식도염(EoE) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Eosinophilic Esophagitis (EoE) Market Outlook

Thelansis's "Eosinophilic Esophagitis (EoE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Eosinophilic Esophagitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Eosinophilic Esophagitis (EoE) Overview

Eosinophilic Esophagitis (EoE), often described as the "asthma of the esophagus," is a chronic, immune-mediated Type 2 inflammatory disease characterized by dense eosinophilic infiltration of the esophageal mucosa, leading to progressive structural remodeling and functional impairment. The disease is driven by Th2-mediated immune pathways and is strongly associated with atopic conditions such as asthma, allergic rhinitis, eczema, and food allergies. Diagnosis is confirmed via endoscopic biopsy demonstrating ≥15 eosinophils per high-power field (eos/hpf), localized to the esophagus.

EoE presents with age-dependent clinical manifestations: Pediatric patients commonly experience vomiting, abdominal pain, regurgitation, and feeding difficulties, while adolescents and adults typically present with dysphagia, food impaction, and chest discomfort, often linked to fibrostenotic changes.

The disease follows a progressive course, transitioning from inflammatory to fibrostenotic phenotypes if not adequately managed.

Current treatment strategies include proton pump inhibitors (PPIs), topical corticosteroids (e.g., budesonide, fluticasone), dietary management, and biologics (e.g., dupilumab) in moderate-to-severe cases. For patients with refractory or severe disease, biologic therapies such as dupilumab (IL-4/IL-13 inhibitor) have significantly advanced treatment by targeting the underlying immunological pathways.

Despite therapeutic advancements, EoE remains a chronic, relapsing condition requiring long-term management, with no curative or disease-modifying therapies currently available.

Key Highlights

• The incident EoE population in the United States is estimated at 27,008 cases in 2025, increasing to 28,897 by 2035, reflecting a steady rise driven by improved diagnosis and awareness.
• The prevalent population is significantly larger, projected to grow from 53,671 in 2025 to 57,423 by 2035, highlighting the chronic nature of the disease and long patient duration.
• The diagnosed population is estimated at 46,693 in 2025, increasing to 49,958 by 2035, indicating gradual improvement in diagnosis rates but still suggesting a gap between prevalence and diagnosis.
• A male predominance is observed, with male cases vs female cases increasing by 2035 (2.2:1 ratio).
• EoE affects a broad age range, with the highest burden observed in young and middle-aged adults (21-40 years), though pediatric cases remain clinically significant.
• Disease severity is largely skewed toward moderate cases, followed by severe and mild segments.
• Dysphagia is the most common symptom, affecting 29,948 patients in 2025, increasing to 32,042 by 2035, followed by abdominal pain/dyspepsia and esophageal structural complications.

Market Overview

• The EoE treatment market in the US is projected to grow from $271 million in 2025 to $370 million by 2035, reflecting a CAGR of 3.2-3.5% over the forecast period.
• Short-term growth (2025-2030) is relatively stronger, driven by increased adoption of biologics and improved diagnosis rates.
• PPIs dominate the market (36-40% share), remaining first-line therapy due to cost-effectiveness and accessibility.
• Topical corticosteroids (fluticasone, budesonide) account for 25-30% combined share.
• Biologics (Dupixent/dupilumab) represent a high-growth segment, with share increasing steadily from 4% in 2025 to 4.6%+ by 2035.
• Emerging therapies such as AK002 (lirentelimab), tezepelumab, and APT-1011 contribute incremental revenue, collectively reaching $70M+ by 2035
• Pharmacological therapies dominate, while dietary and supportive therapies contribute smaller shares but remain clinically relevant.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Sanofi
• AstraZeneca
• NexEos Diagnostics, Inc.
• Celldex Therapeutics
• Eupraxia Pharmaceuticals Inc.
• Revolo Biotherapeutics
• Celgene
• Ellodi Pharmaceuticals, LP
• Phathom Pharmaceuticals, Inc.
• AQILION AB
• Uniquity One (UNI)
• Regeneron Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)